Medtronic Starts MiniMed Exchange Offer with 7% Discount

Medtronic has launched a voluntary exchange offer to divest its remaining interest in MiniMed Group. This program allows shareholders to swap Medtronic stock for MiniMed shares at an approximately 7% discount. This action represents the final step in the medical device company's plan to separate its insulin pump and diabetes management business.

Under the terms of the offer, Medtronic intends to exchange up to 225.4 million shares of MiniMed common stock for outstanding Medtronic ordinary shares. If the offer is oversubscribed, the company retains the option to divest an additional 27.45 million shares to satisfy demand.

"Today's launch reflects our confidence in MiniMed as an independent company and in the opportunities that lie ahead. MiniMed is delivering strong results, has a rich innovation pipeline, and a leadership team with a clear vision for the future," said Geoff Martha, CEO of Medtronic, in a statement regarding the launch.

Mechanics of the Exchange

The exchange offer utilizes a ratio capped at 4.5939 MiniMed shares for every Medtronic share tendered. Based on current valuation metrics, participating shareholders should receive approximately $107.53 in MiniMed stock for every $100 of Medtronic shares exchanged. For U.S. shareholders, the transaction is structured to be tax-free. This is a common feature in corporate spin-offs intended to encourage participation without triggering immediate capital gains liabilities.

As of September 16, 2026, Medtronic PLC (MDT) was trading at $94.14.

Why Spin-offs Matter to Shareholders

Large-cap companies use corporate spin-offs to allow business units to operate with greater agility and focused capital allocation. By separating MiniMed, Medtronic aims to streamline its core portfolio while providing investors with pure-play exposure to the diabetes technology market.

For shareholders, the primary decision involves weighing the growth prospects of the independent MiniMed entity against the stability of the parent company. The 7% discount serves as an incentive for investors to tender their shares, providing a financial benefit to facilitate the divestment of the remaining stake.